149 related articles for article (PubMed ID: 33847293)
1. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
[TBL] [Abstract][Full Text] [Related]
2. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
3. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
4. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Yeoh DK; Campbell AJ; Bowen AC
Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
[No Abstract] [Full Text] [Related]
5. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
8. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV.
Lee YL; Lin KY; Cheng SH; Lu PL; Wang NC; Ho MW; Yang CJ; Liou BH; Tang HJ; Huang SS; Huang SH; Chen TC; Lin CY; Lin SP; Lee YT; Hung CC;
Int J Antimicrob Agents; 2021 Sep; 58(3):106403. PubMed ID: 34289404
[TBL] [Abstract][Full Text] [Related]
9. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
[No Abstract] [Full Text] [Related]
10. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
Sangaré MN; Baril JG; de Pokomandy A; Laprise C; Deshaies C; Klein M; Thomas R; Tremblay C; Roger M; Pexos C; Greenwald Z; Machouf N; Durand M; Hardy I; Dakouo M; Laporte L; Trottier H
Medicine (Baltimore); 2020 Nov; 99(47):e23335. PubMed ID: 33217873
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir: first global approval.
Ballantyne AD; Perry CM
Drugs; 2013 Sep; 73(14):1627-37. PubMed ID: 24052331
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
[No Abstract] [Full Text] [Related]
13. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
Dekker JG; Klaver B; Berkhout B; Das AT
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
[No Abstract] [Full Text] [Related]
15. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Ndashimye E; Arts EJ
Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
Cattaneo D; Sollima S; Meraviglia P; Milazzo L; Minisci D; Fusi M; Filice C; Gervasoni C
Drugs R D; 2020 Jun; 20(2):155-160. PubMed ID: 32189238
[TBL] [Abstract][Full Text] [Related]
18. Compelling evidence for unconditional shift to dolutegravir.
Steegen K; Hans L
Lancet HIV; 2022 Aug; 9(8):e523-e524. PubMed ID: 35905750
[No Abstract] [Full Text] [Related]
19. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
Karabay O
AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
[No Abstract] [Full Text] [Related]
20. Dolutegravir for children with HIV-associated tuberculosis.
Meyers T; Krogstad P
Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
[No Abstract] [Full Text] [Related]
[Next] [New Search]
